adamantane has been researched along with Cardiovascular Stroke in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 32 (88.89) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, MG; Fireman, BH; Graham, DJ; Hamilton, J; Hampp, C; Iyer, A; Lendle, S; Pimentel, M; Reichman, ME; Rucker, M; Toh, S; Zhang, R | 1 |
| Bergmark, BA; Bhatt, DL; Bohula, E; Braunwald, E; Cahn, A; Gurmu, Y; Morrow, DA; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG | 1 |
| Abdel Ghafar, MT; Atlam, R; Elsaadany, A; Eshra, KA; Rizk, FH; Shaaban, AE; Shalaby, MM; Soliman, NA | 1 |
| Anderson, R; Bassi, R; Clark, J; De Nicola, GF; Eaton, P; Fernandez-Caggiano, M; Golforoush, PA; Hutchinson, JP; Kleinjung, J; Laing, A; Marber, MS; Martin, ED; Nichols, C; Thapa, D; Verma, S | 1 |
| Arisi, MF; Atluri, P; Burdick, JA; Chen, CW; Chung, JJ; Gaffey, AC; Gordon, J; Han, J; Kim, ST; Li, E; Tran, Z; Wang, LL; Zaman, S | 1 |
| Assmann, G; Brenner, C; Brunner, S; David, R; Franz, WM; Gross, L; Mueller-Hoecker, J; Nathan, P; Steinbeck, G; Theiss, HD; Vallaster, M; Vogeser, M | 1 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Begum, SS; Hausenloy, DJ; Mocanu, MM; Riksen, N; Theodorou, L; Whittington, HJ; Wynne, AM; Yellon, DM | 1 |
| Smahelová, A; Spinar, J | 1 |
| Standl, E | 1 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Gan'shina, TS; Gnezdilova, AV; Gorbunov, AA; Khaĭlov, NA; Kurdiumov, IN; Lebedeva, MA; Maslennikov, DV; Mirzoian, RS | 1 |
| Gallwitz, B; Nitschmann, S | 1 |
| Bossi, AC; Candido, R; Cioffi, G; Di Lenarda, A | 1 |
| Bhatt, DL; Braunwald, E; Cavender, MA; Corbalan, R; Davidson, JA; Frederich, R; He, P; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Nicolau, JC; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA | 1 |
| Abadeh, A; Advani, A; Advani, SL; Connelly, KA; Desjardins, JF; Gilbert, RE; Kabir, G; Mitchell, M; Thai, K; Zhang, Y | 1 |
| Dangi-Garimella, S | 1 |
| Bhatt, DL; Bonnici, F; Braunwald, E; Cahn, A; Frederich, R; Hirshberg, B; Kumar, KM; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Smahelova, A; Stahre, C; Teoh, H | 1 |
| Dicembrini, I; Mannucci, E | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Kumfu, S; Lekawanvijit, S; Pongkan, W | 1 |
| Nishikido, T; Node, K; Ohira, H; Oyama, J | 1 |
| Ishikawa, S; Kouzu, H; Kuno, A; Miki, T; Miura, T; Murase, H; Nishizawa, K; Ogasawara, M; Tanno, M; Tobisawa, T; Yano, T | 1 |
| Bhatt, DL; Cahn, A; Davidson, J; Hirshberg, B; Mosenzon, O; Raz, I; Rozenberg, A; Scirica, BM; Stahre, C; Strojek, K; Wei, C; Yanuv, I | 1 |
| Bhatt, DL; Braunwald, E; Cahn, A; Cavender, MA; Davidson, J; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG | 1 |
| Ford, L; Khan, JM; McIlroy, G | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Lekawanvijit, S | 1 |
| Alkayed, NJ; Cao, Z; Iliff, J; Liu, L; Merkel, MJ; Motoki, A; Packwood, WH; Van Winkle, DM | 1 |
| Gross, GJ; Nithipatikom, K | 1 |
| Alexander, JH; Berglind, N; Chen, R; Donovan, M; Fiedorek, FT; Frederich, R; Harris, S; Mahaffey, KW; Wolf, R | 1 |
| Thompson, CA | 1 |
| de Boer, RA; Meissner, M; Silljé, HH; van Gilst, WH; Yin, M | 1 |
| Bhatt, DL; Braunwald, E; Chen, R; Davidson, J; Hirshberg, B; Ohman, P; Price, DL; Raz, I; Scirica, BM; Steg, PG; Udell, J | 1 |
| Bellien, J; Bounoure, F; Dreano, Y; Glevarec, E; Lucas, D; Merabet, N; Mulder, P; Nicol, L; Remy-Jouet, I; Thuillez, C; Wecker, D | 1 |
| Butler, MG; Daniel, GW; Fireman, B; Go, AS; Graham, DJ; Joffe, HV; Nelson, JC; Selby, JV; Toh, S | 1 |
| Campbell, WB; Falck, JR; Gauthier, KM; Gross, GJ; Hammock, BD; Moore, J; Nithipatikom, K | 1 |
2 review(s) available for adamantane and Cardiovascular Stroke
| Article | Year |
|---|---|
Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Myocardial Infarction; Patient Outcome Assessment; Patient Selection; Piperidines; Research Design; Time Factors; Uracil | 2015 |
Soluble epoxide hydrolase: a new target for cardioprotection.
Topics: Adamantane; Animals; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Dose-Response Relationship, Drug; Drug Design; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Arrest; Humans; Lauric Acids; Mice; Mice, Knockout; Myocardial Contraction; Myocardial Infarction; Urea | 2009 |
11 trial(s) available for adamantane and Cardiovascular Stroke
| Article | Year |
|---|---|
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.
Topics: Adamantane; Aged; Body Mass Index; Calibration; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Endpoint Determination; Female; Humans; Life Style; Male; Middle Aged; Myocardial Infarction; Registries; Risk Assessment; Risk Factors; Secondary Prevention; Stroke | 2018 |
Vildagliptin Recruits Regulatory T Cells in Patients Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adamantane; C-Reactive Protein; CD4 Lymphocyte Count; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Interferon-gamma; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitric Oxide; Nitriles; Percutaneous Coronary Intervention; Peroxidase; Pyrrolidines; Serum Albumin; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Vildagliptin | 2018 |
[SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus].
Topics: Adamantane; Aged; Cross-Sectional Studies; Czech Republic; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Diseases; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis | 2013 |
[The SAVOR-TIMI 53 study].
Topics: Adamantane; Brain Ischemia; Diabetes Mellitus, Type 2; Dipeptides; Humans; Hypoglycemic Agents; Myocardial Infarction; Research Design | 2014 |
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Renal Insufficiency; Severity of Illness Index; Stroke; Treatment Outcome | 2015 |
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome | 2015 |
The effects and safety of vildagliptin on cardiac function after acute myocardial infarction.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Electrocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Function Tests; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Nitriles; Pyrrolidines; Reference Values; Risk Assessment; Stroke Volume; Treatment Outcome; Vildagliptin | 2015 |
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Myocardial Infarction; Osteoporotic Fractures; Risk Factors; Thiazolidinediones | 2015 |
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Risk; Stroke | 2016 |
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Risk; Stroke | 2010 |
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; France; Humans; Israel; Male; Middle Aged; Myocardial Infarction; Research Design; Survival Analysis; Treatment Outcome; United States | 2011 |
23 other study(ies) available for adamantane and Cardiovascular Stroke
| Article | Year |
|---|---|
Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.
Topics: Acute Disease; Adamantane; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Insulin, Long-Acting; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Product Surveillance, Postmarketing; Propensity Score; Proportional Hazards Models; Prospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; United States | 2018 |
The TAB1-p38α complex aggravates myocardial injury and can be targeted by small molecules.
Topics: Adamantane; Adaptor Proteins, Signal Transducing; Animals; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Female; Gene Knock-In Techniques; HEK293 Cells; Humans; Male; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinase 14; Mutation; Myocardial Infarction; Myocardium; Phosphorylation; Protein Binding; Protein Interaction Domains and Motifs; Reperfusion Injury | 2018 |
Delayed delivery of endothelial progenitor cell-derived extracellular vesicles via shear thinning gel improves postinfarct hemodynamics.
Topics: Adamantane; Animals; beta-Cyclodextrins; Cell Hypoxia; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Endothelial Progenitor Cells; Extracellular Vesicles; Fibrosis; Gels; Hemodynamics; Human Umbilical Vein Endothelial Cells; Humans; Hyaluronic Acid; Inflammation Mediators; Myocardial Infarction; Myocardium; Neovascularization, Physiologic; Rats, Wistar; Time Factors; Time-to-Treatment | 2020 |
Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.
Topics: Adamantane; Animals; Cell Survival; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Heart; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Topics: Adamantane; Animals; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitriles; Pyrazines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Glucagon; Severity of Illness Index; Signal Transduction; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
[Cerebrovascular pharmacology of separate and combined vascular pathology of brain and heart].
Topics: Adamantane; Animals; Animals, Outbred Strains; Benzimidazoles; Bicuculline; Cerebral Cortex; Dopamine; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Ischemic Attack, Transient; Male; Melatonin; Morpholines; Myocardial Infarction; Nimodipine; Picolines; Rats; Receptors, GABA; Structure-Activity Relationship; Vasodilation; Vasodilator Agents | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
Topics: Adamantane; Animals; Benzylamines; Cardiac Catheterization; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds; Hypoglycemic Agents; Liraglutide; Male; Myocardial Infarction; Rats; Rats, Inbred F344 | 2016 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Enalapril; Fibrosis; Heart Rate; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Myocardium; Nitriles; Oxidative Stress; Pyrrolidines; Rats, Wistar; Recovery of Function; Signal Transduction; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Vildagliptin | 2015 |
Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.
Topics: Adamantane; Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Chloroquine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Administration Schedule; Injections, Subcutaneous; Male; Microtubule-Associated Proteins; Myocardial Infarction; Myocardium; Nitriles; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats, Inbred OLETF; Signal Transduction; Time Factors; Ventricular Function, Left; Vildagliptin | 2015 |
Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report.
Topics: Adamantane; Administration, Inhalation; Adult; Cannabinoids; Designer Drugs; Diagnosis, Differential; Emergency Medical Services; England; Humans; Inhalant Abuse; Male; Myocardial Infarction; Psychotropic Drugs; Toxicokinetics; Treatment Outcome | 2016 |
Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
Topics: Adamantane; Animals; Cardiotonic Agents; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enalapril; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Myocardial Infarction; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Ventricular Remodeling; Vildagliptin | 2016 |
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Topics: 8,11,14-Eicosatrienoic Acid; Adamantane; Animals; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Female; Gene Deletion; Heart Ventricles; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Time Factors; Urea | 2008 |
FDA's first active medical product surveillance eyes antidiabetic-MI link.
Topics: Adamantane; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Myocardial Infarction; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2011 |
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Administration Schedule; Heart Failure; Male; Myocardial Infarction; Nitriles; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Vildagliptin | 2011 |
Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
Topics: Adamantane; Animals; Coronary Circulation; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Heart Failure; Hemodynamics; Lauric Acids; Male; Myocardial Infarction; Myocardium; Nitric Oxide; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Ventricular Function, Left; Ventricular Remodeling | 2012 |
A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
Topics: Adamantane; Cohort Studies; Confounding Factors, Epidemiologic; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Follow-Up Studies; Humans; Hypoglycemic Agents; Myocardial Infarction; Poisson Distribution; Product Surveillance, Postmarketing; Proportional Hazards Models; Regression Analysis; United States; United States Food and Drug Administration | 2012 |
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.
Topics: 8,11,14-Eicosatrienoic Acid; Adamantane; Animals; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Diazoxide; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epoxide Hydrolases; Female; Heart Rate; Lauric Acids; Male; Mitochondria, Heart; Myocardial Infarction; Myocardium; Potassium Channels | 2008 |